KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Current Assets for 16 consecutive years, with $825.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 23.97% to $825.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $825.2 million, a 23.97% decrease, with the full-year FY2025 number at $825.2 million, down 23.97% from a year prior.
  • Current Assets was $825.2 million for Q4 2025 at Halozyme Therapeutics, down from $1.1 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.1 billion in Q4 2024 to a low of $653.2 million in Q3 2022.
  • A 5-year average of $881.6 million and a median of $926.3 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 101.23% in 2021, then plummeted 35.79% in 2022.
  • Halozyme Therapeutics' Current Assets stood at $926.3 million in 2021, then dropped by 20.22% to $739.0 million in 2022, then grew by 1.0% to $746.4 million in 2023, then surged by 45.41% to $1.1 billion in 2024, then decreased by 23.97% to $825.2 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Current Assets are $825.2 million (Q4 2025), $1.1 billion (Q4 2024), and $746.4 million (Q4 2023).